Joel Kellman is a co-founder of GGV Capital. Previously, he was a founder and longtime partner of the Silicon Valley law firm, Fenwick & West LLP. Joel co-managed Fenwick & West’s investments in early stage high technology companies from 1982 to 2000, when he left Fenwick & West to launch GGV Capital. Joel also co-founded KLM Capital, a cross-border venture capital fund, and Utah Ventures.
He is GGV’s Board representative for its investments in Intarcia Therapeutics, Agility (acquired by JDS Uniphase)(NASDAQ: JDSU), QPass (acquired by Amdocs)(NYSE: DOX), 2Wire, Biosensors (SGX: B20.SI) and Xenoport (NASDAQ: XNPT). In addition, Joel was formerly a Board representative for Oculex Pharmaceuticals (sold to Allergan).
Joel is a graduate of SUNY Binghamton and St. Johnâ€™s University Law School and received an LLM in Foreign and Comparative Law from New York University.
Outside of GGV, Joel sweats through bikram yoga and reserves his winters for skiing. He continues to be active with Onevoice, a Palestinian-Israeli peace organization. Joel is also a “Senior Advisor to the Institute” at the Institute for Asia and Asian Diasporas of Binghamton University.